EMVISION MEDICAL DEVICES LIMITED (EMV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EMV

EMV - EMVISION MEDICAL DEVICES LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.22
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.80

21 Aug
2025

-0.020

OPEN

$1.80

-1.10%

HIGH

$1.81

57,006

LOW

$1.76

TARGET
$2.95 63.9% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
EMV: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 3.4 - 9.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-3.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx21.7
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.0 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-23.10 %
Return on Invested Capital xxxxxxxxxxxxxxx-21.18 %
Return on Assets xxxxxxxxxxxxxxx-15.38 %
Return on Equity xxxxxxxxxxxxxxx-23.10 %
Return on Total Capital xxxxxxxxxxxxxxx-91.14 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-6.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx3 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx19 M
Price To Book Value xxxxxxxxxxxxxxx9.97

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.3 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx5 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

01/08/2025

1

Re-initiation of coverage with Speculative Buy

$2.95

63.89%

Bell Potter has re-initiated coverage of EMVision Medical Devices with Speculative Buy rating and target price of $2.95.

The company's portable brain imaging technology has the potential to redefine stroke diagnosis and triage as it uses electromagnetic pulses to distinguish between clotting and bleeding. 

The company is trialing two devices (hospital version weighing 100kgs and portable 12kgs) and the broker expects both will be awarded breakthrough device designation in due course.

The global total addressable market is estimated to be US15bn but the broker's assumptions are based on only the Australian/US markets.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -9.40 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -9.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

EMV STOCK CHART

FNArena News on EMV

1
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
2
Australian Broker Call *Extra* Edition – Feb 06, 2023

Feb 06 2023 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Nov 16, 2022

Nov 16 2022 - Daily Market Reports
4
Who Will Be The Next Pro Medicus?

May 13 2021 - Weekly Reports
5
Rudi’s View: Osteopore, Whitehaven Coal and Telstra

Dec 06 2019 - Rudi's View

Latest Medical Equipment & Devices News

1
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
2
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
3
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
4
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
5
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
6
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
7
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
8
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
9
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
10
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia